CIK 0001394319
TCON Tracon Pharmaceuticals, Inc.
Insider trading from SEC Form 4. Last filing Mar 13, 2024.
In brief
Tracon Pharmaceuticals, Inc. (TCON) has 27 SEC Form 4 filings on file from 11 insiders, the latest filed on Mar 13, 2024. No insider bought or sold on the open market in the last 90 days; rows filed in that time are grants, exercises, tax withholding and other transactions that carry no view on the price.
15 open-market trades have been scored at TCON. The newest: Opaleye Management Inc. (10% owner) sold $1.4M of stock on Nov 10, 2023, filed Nov 14, 2023, scored 57 (moderate). 2 insiders bought within 14 days of each other around Mar 9, 2023.
Last 90 days
Signals
Open-market buys and sells at Tracon Pharmaceuticals, Inc., scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 57Moderate | Opaleye Management Inc. owner sell | $1.4M 4,764,008 shares | -110% | - | |
| 39Weak | Charles Theuer President and CEO buy | $38k 50,999 shares | +15% | - | |
| 43Moderate | Opaleye Management Inc. owner buy | $241k 174,508 shares | +4% | - | |
| 38Weak | Charles Theuer President and CEO buy | $7,600 5,000 shares | +1% | - | |
| 15Weak | William R Larue director sell | $151 120 shares | -2% | - | |
| 30Weak | Charles Theuer President and CEO buy | $11k 6,800 shares | +2% | - | |
| 25Weak | Scott B. Brown Chief Financial Officer buy | $5,215 3,500 shares | +19% | - | |
| 42Moderate | Opaleye Management Inc. owner buy | $210k 167,500 shares | +4% | - | |
| 46Moderate | Charles Theuer President and CEO buy | $30k 23,000 shares | +7% | - | |
| 12Weak | Opaleye Management Inc. owner sell | $2,216 1,539 shares | -0% | - | |
| 30Weak | Charles Theuer President and CEO buy | $20k 13,900 shares | +5% | - | |
| 30Weak | Charles Theuer President and CEO buy | $14k 9,200 shares | +3% | - | |
| 30Weak | Charles Theuer President and CEO buy | $9,540 6,000 shares | +2% | - | |
| 20Weak | Opaleye Management Inc. owner buy | $21k 12,500 shares | +0% | - | |
| 33Weak | Charles Theuer President and CEO buy | $8,850 5,000 shares | +2% | - |
Transactions
Every row filed, 37 in all.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Apr 20, 2023 | Charles Theuer PRESIDENT AND CEO | AGrant or award Common Stock | +3,500 | $0.14 | $482 | 402,917 | Mar 13, 2024 |
| Apr 20, 2023 | Scott B. Brown CHIEF FINANCIAL OFFICER | AGrant or award Common Stock | +3,500 | $0.14 | $482 | 25,128 | Mar 13, 2024 |
| Mar 12, 2024 | Scott B. Brown CHIEF FINANCIAL OFFICER | AGrant or award Employee Stock Option (Right to Buy)derivative | +224,800 | $0.00 | $0 | 224,800 | Mar 13, 2024 |
| Oct 20, 2023 | Charles Theuer PRESIDENT AND CEO | AGrant or award Common Stock | +3,500 | $0.13 | $467 | 406,417 | Mar 13, 2024 |
| Mar 12, 2024 | Charles Theuer PRESIDENT AND CEO | AGrant or award Employee Stock Option (Right to Buy)derivative | +518,300 | $0.00 | $0 | 518,300 | Mar 13, 2024 |
| Nov 10, 2023 | Opaleye Management Inc. owner | SOpen-market sale Common Stock, par value $0.001 per shareindirect: By Opaleye, L.P. | -4,324,008 | $0.29 | $1.3M | 0 | Nov 14, 2023 |
| Nov 10, 2023 | Opaleye Management Inc. owner | SOpen-market sale Common Stock, par value $0.001 per shareindirect: By Managed account | -440,000 | $0.29 | $129k | 0 | Nov 14, 2023 |
| Apr 26, 2023 | Charles Theuer President and CEO | POpen-market purchase Common Stock | +3,999 | $0.66 | $2,639 | 352,417 | Apr 28, 2023 |
| Apr 27, 2023 | Charles Theuer President and CEO | POpen-market purchase Common Stock | +47,000 | $0.75 | $35k | 399,417 | Apr 28, 2023 |
| Apr 19, 2023 | Lisa Johnson-Pratt director | AGrant or award Director Stock Option (Right to Buy)derivative | +18,000 | $0.00 | $0 | 18,000 | Apr 21, 2023 |
| Apr 19, 2023 | William R Larue director | AGrant or award Director Stock Option (Right to Buy)derivative | +18,000 | $0.00 | $0 | 18,000 | Apr 21, 2023 |
| Apr 19, 2023 | Carol C. Lam director | AGrant or award Director Stock Option (Right to Buy)derivative | +18,000 | $0.00 | $0 | 18,000 | Apr 21, 2023 |
| Apr 19, 2023 | Martin A Mattingly director | AGrant or award Director Stock Option (Right to Buy)derivative | +18,000 | $0.00 | $0 | 18,000 | Apr 21, 2023 |
| Apr 19, 2023 | Saundra L Pelletier director | AGrant or award Director Stock Option (Right to Buy)derivative | +18,000 | $0.00 | $0 | 18,000 | Apr 21, 2023 |
| Apr 19, 2023 | J Rainer Twiford director | AGrant or award Director Stock Option (Right to Buy)derivative | +18,000 | $0.00 | $0 | 18,000 | Apr 21, 2023 |
| Apr 19, 2023 | Stephen T Worland director | AGrant or award Director Stock Option (Right to Buy)derivative | +18,000 | $0.00 | $0 | 18,000 | Apr 21, 2023 |
| Mar 9, 2023 | Opaleye Management Inc. owner | POpen-market purchase Common Stock, par value $0.001 per shareindirect: By Opaleye, L.P. | +174,508 | $1.38 | $241k | 4,324,508 | Mar 13, 2023 |
| Feb 28, 2023 | Charles Theuer President and CEO | POpen-market purchase Common Stock | +200 | $1.52 | $304 | 340,118 | Mar 2, 2023 |
| Mar 1, 2023 | Charles Theuer President and CEO | POpen-market purchase Common Stock | +4,800 | $1.52 | $7,296 | 344,918 | Mar 2, 2023 |
| Feb 1, 2023 | Bonne J. Adams Chief Operating Officer | AGrant or award Employee Stock Option (Right to Buy)derivative | +99,000 | $0.00 | $0 | 99,000 | Feb 9, 2023 |
| Feb 1, 2023 | Scott B. Brown Chief Financial Officer | AGrant or award Employee Stock Option (Right to Buy)derivative | +144,000 | $0.00 | $0 | 144,000 | Feb 3, 2023 |
| Feb 1, 2023 | Charles Theuer President and CEO | AGrant or award Employee Stock Option (Right to Buy)derivative | +332,000 | $0.00 | $0 | 332,000 | Feb 3, 2023 |
| Jan 18, 2023 | Charles Theuer President and CEO | POpen-market purchase Common Stock | +6,800 | $1.62 | $11k | 339,918 | Jan 19, 2023 |
| Dec 21, 2022 | William R Larue director | SOpen-market sale Common Stock | -120 | $1.26 | $151 | 7,763 | Jan 19, 2023 |
| Dec 29, 2022 | Scott B. Brown Chief Financial Officer | POpen-market purchase Common Stock | +3,500 | $1.49 | $5,215 | 21,628 | Jan 3, 2023 |
| Dec 14, 2022 | Opaleye Management Inc. owner | POpen-market purchase Common Stock, par value $0.001 per shareindirect: By Opaleye, L.P. | +140,000 | $1.26 | $176k | 4,150,000 | Dec 16, 2022 |
| Dec 14, 2022 | Opaleye Management Inc. owner | POpen-market purchase Common Stock, par value $0.001 per shareindirect: By Managed Account. | +27,500 | $1.24 | $34k | 440,000 | Dec 16, 2022 |
| Dec 14, 2022 | Charles Theuer President and CEO | POpen-market purchase Common Stock | +23,000 | $1.29 | $30k | 333,118 | Dec 15, 2022 |
| Dec 6, 2022 | Opaleye Management Inc. owner | XIn-the-money exercise Common Stock, par value $0.01 per shareindirect: By Opaleye, L.P. | +221,539 | $0.01 | $2,215 | 4,011,539 | Dec 8, 2022 |
| Dec 6, 2022 | Opaleye Management Inc. owner | SOpen-market sale Common Stock, par value $0.01 per shareindirect: By Opaleye, L.P. | -1,539 | $1.44 | $2,216 | 4,010,000 | Dec 8, 2022 |
| Dec 6, 2022 | Opaleye Management Inc. owner | XIn-the-money exercise Prefunded Warrantsderivativeindirect: By Opaleye, L.P. | -221,539 | $0.01 | $2,215 | 1,667,974 | Dec 8, 2022 |
| Nov 18, 2022 | Charles Theuer President and CEO | POpen-market purchase Common Stock | +13,900 | $1.41 | $20k | 310,118 | Nov 22, 2022 |
| Nov 3, 2022 | Charles Theuer President and CEO | POpen-market purchase Common Stock | +9,200 | $1.52 | $14k | 296,218 | Nov 4, 2022 |
| Nov 2, 2022 | Charles Theuer President and CEO | POpen-market purchase Common Stock | +6,000 | $1.59 | $9,540 | 287,018 | Nov 3, 2022 |
| Oct 18, 2022 | Opaleye Management Inc. owner | POpen-market purchase Common Stock, par value $0.001 per shareindirect: By Opaleye, L.P. | +10,000 | $1.65 | $17k | 3,790,000 | Oct 19, 2022 |
| Oct 18, 2022 | Opaleye Management Inc. owner | POpen-market purchase Common Stock, par value $0.001 per shareindirect: By Managed Account. | +2,500 | $1.65 | $4,125 | 4,125,000 | Oct 19, 2022 |
| Oct 7, 2022 | Charles Theuer President and CEO | POpen-market purchase Common Stock | +5,000 | $1.77 | $8,850 | 277,518 | Oct 11, 2022 |
Insiders
Everyone who has filed a Form 4 here.
- Bonne J. AdamsChief Operating Officer
- Scott B. BrownChief Financial Officer
- Lisa Johnson-Prattdirector
- William R Laruedirector
- Carol C. Lamdirector
- Martin A Mattinglydirector
- Opaleye Management Inc.owner, other
- Saundra L Pelletierceo, officer, director
- Charles TheuerPresident and CEO
- J Rainer Twiforddirector
- Stephen T Worlandceo, officer, director
Questions about TCON
Answered from the filings on this page, as of the latest one.
Are insiders buying TCON?
No. In the last 90 days no insider at Tracon Pharmaceuticals, Inc. bought or sold shares on the open market according to SEC Form 4 filings. The rows on file from that period are grants, exercises, tax withholding or other transactions, which carry no view on the price.
Who was the last insider to trade TCON on the open market?
Opaleye Management Inc. (10% owner) sold $1.4M of TCON on Nov 10, 2023 and filed the Form 4 on Nov 14, 2023. InsiderTell scored 57 (moderate).
How many insiders file Form 4 at Tracon Pharmaceuticals, Inc.?
11 people have filed a Form 4 at Tracon Pharmaceuticals, Inc., among them Bonne J. Adams (Chief Operating Officer), Scott B. Brown (Chief Financial Officer), Lisa Johnson-Pratt (director). Officers, directors and holders of more than 10% of a share class must report their trades within two business days.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.